NRx Pharmaceuticals (NRXP) announced that on January 17, it received written notice from the Nasdaq Listing Qualifications Staff stating that the company regained compliance with the market value of listed Securities requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market, and the matter is now closed.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRX Pharmaceuticals Announces Board Resignation and New Nominee
- NRx Pharmaceuticals files to uplist securities to Nasdaq Global Market
- NRx Pharmaceuticals, HOPE sign term sheet for $27M in funding
- HOPE Therapeutics announces planned acquisition of Dura Medical
- NRx Pharmaceuticals, Hope announce planned acquisition of Kadima